Visit Your Local PBS Station PBS Home PBS Home Programs A-Z TV Schedules Watch Video Support PBS Shop PBS Search PBS
Research & Resources

Learn More
Get RSS feed.
Print Story Email Story

Where Best to Invest - GENERIC DRUGS

Tuesday, January 09, 2007

According to NBR Market Monitor Al Goldman of AG Edwards, the stocks of generic drug makers will make strong gains in 2007. NBR's Dana Greenspon reports on the sector, which should benefit from expired patents and a Congress controlled by Democrats.

Click to Read Transcript.

Image of pharmacist separating generic drugs. Click to watch report. Watch the Report.
Return to the "Where Best to Invest" Homepage
William Sawyer's Picks
William Sawyer is a Generic Drug Analyst with Leerink Swann. In Dana Greenspon's report, Sawyer recommends three generic drug makers. Those firms are listed below.
A graphic listing William Sawyer's Generic Drug Maker Picks.
Related NBR Stories & Links
External Links/Articles*

  • FDA Office of Generic Drugs
    Information about generic drugs from the agency responsible for their approval. The site explains the approval process for generics, provides links to lists of available generics, and details the requirements for generic qualification.
  • Barr Pharmaceuticals
    Barr is on one of analyst William Sawyer's picks for 2007. The company's generic products are marketed under the “Barr Pharmaceuticals” label, and its proprietary products – such as the Plan B emergency contraception pill – are marketed under the “Duramed Pharmaceuticals” label. Barr's CEO, Bruce Downey, is interviewed in Dana Greenspon's report.
  • Generic Pharmaceutical Association
    The Generic Pharmaceutical Association represents the manufacturers and distributors of generic drugs, as well as suppliers of other goods and services to the generic pharmaceutical industry.
  • IMS Health
    IMS is a medical data reseach firm that provides market data on the pharmaceutical industry..
  • Generic Biologics Legislation
    This site provides information on the bill introduced by Democratic Congressman Henry Waxman that would create an approval pathway for generic biologics. The site has links to the bill text, the bill summary, and background on the issue.

    • *Clicking these external links will take you off the NBR web site on PBS.org. NBR has no affiliation with these sites.